Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a new version of the document. This appears to be an administrative update with no visible changes to the study details or data presented.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThe record page reflects a newer update timestamp/version and expands the listed study sites by adding additional participating hospitals in Japan and China, increasing the total number of locations from 80 to 86. Other displayed changes are version/date-related rather than changes to trial design or key clinical details.SummaryDifference0.6%

- Check37 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check66 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0. It seems to be an internal version update rather than a modification to visible page content.SummaryDifference0.0%

- Check73 days agoChange DetectedAdded two new study sites: National and Kapodistrian University of Athens – School of Health Sciences – Faculty of Medicine (Athens, Greece) and Shanghai Jiao Tong University School of Medicine – Renji Hospital (Shanghai, China). Total number of locations updated to 80.SummaryDifference0.3%

- Check101 days agoChange DetectedNew study sites were added, including Universitaetsklinikum Hamburg-Eppendorf (Hamburg, Germany), Sichuan Provincial Academy of Medical Sciences and Sichuan Provincial People’s Hospital (Chengdu, China), Peking Union Medical College Hospital (Beijing, China), Multiprofile hospital for active treatment Kaspela EOOD (Plovdiv, Bulgaria), and University of North Carolina School of Medicine (Chapel Hill, NC). The total number of locations is now 78.SummaryDifference0.9%

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.